TipRanks
Genworth Financial Inc (MX:GNW)
:GNW
Mexico Market
EarningsQ2 2026 Earnings Report

Genworth Financial (GNW) Q2 2026 Earnings Report

0 Followers

MX:GNW Q2 2026 EPS Results

Actual EPS$5.31
Consensus EPS$5.12
Beat/MissBeat by +$0.18
One Year Ago EPS$2.93

MX:GNW Q2 2026 Revenue Results

Actual Revenue$32.67B
Expected Revenue―
Beat/Miss―
YoY Revenue Growth+2.29%

Earnings Announcement Details

QuarterQ2 2026
Date08/05/2026
TimeAfter Close
Conference CallWednesday, August 5, 2026
MX:GNW Upcoming Earnings
Genworth Financial's next earnings date is estimated for November 11, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

MX:GNW Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 05, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented a mix of strong execution and clear progress on strategic priorities—notably Enact's robust underwriting results, sizable capital returns, disciplined share repurchases, and tangible CareScout network expansion—while also acknowledging meaningful near-term headwinds from closed-block GAAP losses (A-to-E remeasurements), ongoing CareScout investment burn with matches pacing below target, and constrained holding-company liquidity. Overall, the positives (steady cash generation from Enact, committed capital allocation, and strategic growth investments) offset the acknowledged risks, but the company faces execution and volatility risks in closed-block experience and scaling CareScout.
Company Guidance
The company reiterated detailed 2026 guidance anchored by expected Enact capital returns of $550–$600 million (Genworth’s ~81% share = $445–$485 million), an increased share-repurchase plan of $225–$250 million for the year, and a CareScout growth plan targeting ~7.5k matches in 2026 (vs. 3.25k in 2025) even though current pacing is below that level; CareScout recorded ~1.45k matches in Q2 and ~2.95k in H1, generated $6M of Q2 revenue ($12M H1) with full-year revenue still expected at $25M, and will see $50–$55M of 2026 investment (CareScout Insurance requires no additional 2026 capital after an $85M 2025 investment). Additional metrics: Enact returned $103M in Q2, wrote $15B of new insurance in the quarter with $274B primary insurance in force, and Genworth’s share of Enact book value (incl. AOCI) was $4.4B with an estimated PMIER sufficiency of 161% (~$1.9B above requirements); the closed block secured $46M of gross incremental premium approvals in Q2 (+$27M in July), has cumulatively achieved ~$34.8B NPV of benefit reductions/premium increases since 2012 and expects 2026 approvals/benefit reductions to contribute ~ $1B NPV, while A-to-E losses imply a ~ $300M full-year benchmark (H1 has trended higher). Holding company liquidity and capital structure metrics include $215M of cash and liquid assets (excluding ~$81M held for obligations), $768M of holding company debt, a cash interest coverage ratio of ~9x, $62M of buybacks in the quarter at an $8.74 average (plus $4M in July; ~$922M repurchased since May 2022 at a $6.48 average), cash yields in life companies of ~6.2%, targeted ~12% returns on alternatives, and an unsettled AXA litigation with a potential $750M recovery (decision expected in ~3–6 months) that is not included in current plans.
Strong Enact Performance and Capital Returns
Enact delivered adjusted operating income of $143 million to Genworth in Q2 and returned $103 million of capital to Genworth during the quarter. Enact now expects to return $550–$600 million in 2026 (Genworth share ~ $445–$485 million based on ~81% ownership). Enact's estimated PMIER sufficiency ratio remained strong at 161%, approximately $1.9 billion above requirements.
Solid Consolidated and Segment Earnings (Excluding Closed Block)
Genworth reported net income of $47 million ($0.12 per share) for Q2 and adjusted operating income excluding the closed block of $112 million ($0.29 per share).
Active and Disciplined Share Repurchase Program
Since the initial authorization in May 2022, Genworth repurchased approximately $922 million of shares at an average price of $6.48 through July 31. In Q2 the company repurchased $62 million at an average price of $8.74 per share (plus $4 million in July). Full-year 2026 repurchase guidance was increased to $225–$250 million.
Enact Growth Metrics
Enact wrote $15 billion of new insurance in the quarter; primary insurance in force increased 2% year-over-year to $274 billion. Earned premiums were $245 million in the quarter. A favorable pretax reserve release of $37 million drove a low loss ratio of 14% for Enact.
CareScout Network and Product Expansion
CareScout expanded the network to more than 1.1k home care locations and added senior living communities; the company doubled the number of local advisers with representation in 26 states. A CareScout worksite insurance product is approved and ready for a Q3 launch in at least 34 states.
Rapid Increase in CareScout Matches
CareScout facilitated ~1.45k matches in Q2 and ~2.95k matches in H1 2026 — over double the number of matches in H1 2025 (>100% year-over-year growth).
Progress on Closed-Block Risk Reduction
Since 2012 Genworth has achieved approximately $34.8 billion (NPV) of benefit reductions and premium increases. Exposure to 5% compound inflation options decreased to ~35% (from 57% in 2014) and the percentage of policies with lifetime benefits decreased to 11% (from 24% in 2014).
Conservative Investment Positioning and Yields
Majority of assets are investment-grade fixed maturities. Cash in life insurance companies invested at approximately 6.2% in the quarter. Alternative assets program targets ~12% returns and realizations helped drive higher investment income in Q2.

MX:GNW Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Nov 11, 2026
2026 (Q3)
5.05 / -
0.732―
2026 (Q2)
5.12 / 5.31
2.92781.25% (+2.38)
2026 (Q1)
3.20 / 3.49
2.19559.17% (+1.30)
2025 (Q4)
2.93 / 0.37
0.732-50.00% (-0.37)
2025 (Q3)
1.83 / 0.73
2.012-63.64% (-1.28)
2025 (Q2)
1.92 / 2.93
5.122-42.86% (-2.20)
2025 (Q1)
3.84 / 2.20
3.476-36.84% (-1.28)
2024 (Q4)
3.11 / 0.73
-9.33107.84% (+10.06)
2024 (Q3)
3.48 / 2.01
1.64722.22% (+0.37)
2024 (Q2)
2.20 / 5.12
3.29355.56% (+1.83)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed